Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2010 Mar 8:10:18.
doi: 10.1186/1471-2288-10-18.

Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

Affiliations
Meta-Analysis

Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

Laurent Coudeville et al. BMC Med Res Methodol. .

Abstract

Background: Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy.

Methods: We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information.

Results: A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals.

Conclusion: Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Directed acyclic graph of the interval-censored model with covariates. Square boxes represent fixed quantities, white circles stochastic nodes, grey circles logical nodes, solid arrows stochastic dependencies and dashed arrows deterministic dependencies. Bold lines corresponds to nodes associated with data.
Figure 2
Figure 2
Gelman-Rubin diagnostic plot (a) and kernel densities (b) (ALL model). GR plot: blue corresponds to within-chain variability, green to between chain variability and red to their ratio.
Figure 3
Figure 3
Estimated (Y-axis) versus observed (X-axis) number of influenza cases for the 37 datasets considered in the analysis (ALL model). Red corresponds to vaccinees, blue to non vaccines, grey to unknown status, circles to type A strain and triangles to type B.
Figure 4
Figure 4
Estimated probability of protection according to the level of HI titre. (All Model - Posterior Mean value and 95% credible interval).

Similar articles

Cited by

References

    1. WHO. Factsheet number 211. World Health Organization; 2008. Influenza factsheet.http://www.who.int/mediacentre/factsheets/fs211/en/index.html 14-3-2008.
    1. Palmer DF, Dowdle WR, Coleman MT, Schild GC. Advanced laboratory technicals for immunological diagnostic. US Department of Health; 1975.
    1. Committee for Proprietary Medicinal Products (CPMP) Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. EMEA. 1997.
    1. Wood JM, Levandowski RA. The influenza vaccine licensing process. Vaccine. 2003;21:1786–1788. doi: 10.1016/S0264-410X(03)00073-2. - DOI - PubMed
    1. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972;70:767–777. - PMC - PubMed